T cells

[Scientific Reports] Participants playing up to 540 in cumulative match time and less than 30 min in each single match during the observation period formed the control group. White blood cell phenotyping and creatine kinase plasma activity analyses were performed.

[Oncogene] Despite its well-documented inhibitory effects, higher PD-1 expression in tumor-infiltrating lymphocytes was significantly associated with longer survival in triple-negative breast cancer patients.

[Bone Marrow Transplantation] Mice were followed for xenogeneic graft-versus-host disease score and survival. Human T-cell engraftment and as well as human T-cell subtypes were monitored in blood on days 14, 21, and 28 after transplantation.

[Leukemia] With the development of the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin, the CD3-CD19 bispecific T-cell engager antibody blinatumomab, CD19 chimeric antigen receptor T-cell therapy, and the potent BCR-ABL1 tyrosine kinase inhibitor ponatinib, the outlook of acute lymphoblastic leukemia in both younger and older adults has substantially improved.

[Duke-NUS] In a move that will bring hope to liver transplant patients around the world, Lion TCR, a Singapore biotechnology company, has signed an exclusive worldwide licensing agreement with Duke-NUS Medical School to develop an innovative method of using gene-edited T cells to treat recurring cancers in the donated organ.

[Scientific Reports] Investigators demonstrated efficient T cell transduction with the melanoma-reactive TIL1383I TCR through culturing with interleukin 7 (IL-7) in the absence of CD3 activation.